Almurtide

Muramyl Dipeptide (MDP) Analogue / Immunomodulatory PeptideRx: ResearchCompound: Research

Also known as: MDP-butyl ester, Murabutide, N-acetylmuramyl-L-alanyl-D-glutamine n-butyl ester

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Almurtide (murabutide) is a synthetic immunomodulatory muramyl dipeptide analogue investigated for its ability to enhance nonspecific immune defenses. It has been studied as an adjuvant and immunostimulant in infectious disease contexts, including HIV infection, and as a potential cancer immunotherapy adjuvant. It demonstrated a favorable tolerability profile compared to earlier MDP analogues.

Mechanism of Action

Almurtide is a synthetic analogue of muramyl dipeptide (MDP), a component of bacterial cell walls. It activates innate immunity primarily through NOD2 receptor signaling, stimulating macrophage and monocyte activation, enhancing cytokine production (IL-1, TNF-α, IL-6), and augmenting nonspecific host defense mechanisms.

Routes of Administration

IntravenousSubcutaneous

Goals & Uses

  • Vaccine adjuvantVaccinologyLow
  • Immunostimulation / innate immune activationImmunologyModerate
  • Cancer immunoadjuvantOncologyLow
  • HIV infection adjunct therapyInfectious DiseaseModerate

Contraindications

  • Known hypersensitivity to MDP analoguesAllergy/ImmunologyHigh
  • Autoimmune disease (active)ImmunologicalModerate

Adverse Effects

  • Injection site reactionsLocalCommon
  • Transient fever / flu-like symptomsSystemicUncommon
  • Transient leukocytosisHematologicalUncommon
  • FatigueGeneralUncommonLow energy or tiredness

Drug Interactions

  • Immunosuppressants (e.g., corticosteroids, cyclosporine)Moderate
  • Antiretroviral therapy (ART)Low

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Pediatric patientsAgeRelative
  • Severely immunocompromised patientsImmunologicalRelative

Regulatory Status

  • European UnionInvestigationalInvestigated in European clinical trials, particularly in France, for HIV and immune modulation; not approved.
  • United StatesUnapprovedNot approved by the FDA for any indication; research use only.
  • United KingdomUnknownNo known UK regulatory approval; research compound.

Almurtide (murabutide) has not received FDA, EMA, or other major regulatory approval for any indication. It has been studied in clinical trials in Europe, particularly in France, for HIV infection and as an immunoadjuvant. It remains a research/investigational compound.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack